SPR1
Cancers with Hippo-driver mutations/aberrations & YAP/TAZ hyperactivation
IND EnablingActive
Key Facts
Indication
Cancers with Hippo-driver mutations/aberrations & YAP/TAZ hyperactivation
Phase
IND Enabling
Status
Active
Company
About Sporos Biodiscovery
Sporos Biodiscovery is a private, preclinical biotech founded in 2021 and based in San Diego. The company is advancing a pipeline of small molecules targeting tumor-intrinsic pathways and the immunosuppressive tumor microenvironment, with its most advanced candidate, SPR1 (a TEAD1/4 inhibitor), in IND-enabling studies. Sporos leverages a genetically-validated framework and a team of seasoned drug developers and cancer biologists to build its portfolio, aiming to overcome resistance to existing therapies like MAPK inhibitors and immuno-oncology agents.
View full company profile